Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 26.5¢ | Day High | 29.0¢ | Day Low | 26.5¢ | |||
| Daily Volume | 1305615 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 2 | 27.0¢ | 31811 | 3 | 28.5¢ | 42377 | |
| Mr. Paul Rennie | Executive Chairman of the Board, Managing Director |
| Ms. Abby Macnish Niven | Chief Financial Officer, Company Secretary |
| Mr. Matthew James Fry | Non-Executive Independent Director |
| Mr. Amos Meltzer | Non-Executive Independent Director |
Data source: Refinitiv
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.005(1.89%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 29.0¢ | 26.5¢ | $362.3K | 1.305M |
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31811 | 27.0¢ |
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 42377 | 3 |
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| PAR (ASX) Chart |
